Welcome to our dedicated page for Splash Beverage Group news (Ticker: SBEV), a resource for investors and traders seeking the latest updates and insights on Splash Beverage Group stock.
Splash Beverage Group, Inc. reports developments for a portfolio of alcoholic and non-alcoholic beverage brands. Its recurring updates cover brand distribution for Pulpoloco sangria, SALT flavored tequilas, Copa di Vino wine by the glass, and hydration or recovery drinks, including retail authorizations and state-level alcohol-market access.
Company news also includes operating and financial results calls, capital-structure updates, private-placement activity, material agreements, shareholder voting matters, and governance changes. These items reflect Splash Beverage Group's model of managing and expanding consumer beverage brands through retail channels, distribution relationships, and public-company financing activity.
Splash Beverage Group (NYSE American: SBEV) announced two major steps to advance its NYSE American compliance plan and strengthen its balance sheet. The company settled approximately $3.3 million of legacy accounts payable and accrued liabilities for about $550,000 in cash, expecting an approximate $2.75 million gain from extinguishment of indebtedness, subject to final accounting review. The settlements are expected to remove roughly 84% of the negotiated obligations while paying about 17% of their face value.
The board also approved a 1-for-4 reverse stock split of common shares. Outstanding shares will be reduced from about 25.2 million to 6.3 million, and authorized shares from 400 million to 100 million. No fractional shares will be issued; fractions will be rounded down to the nearest whole share. The split becomes effective after market close on July 24, 2026, with post-split trading starting July 27, 2026 under the symbol SBEV with new CUSIP 84862C401. According to Splash Beverage, the reverse split is intended to help maintain compliance with NYSE American minimum share price requirements.
Splash Beverage Group (NYSE American:SBEV) announced that NYSE American has accepted its plan to regain compliance with continued listing standards and granted a compliance period through January 29, 2027.
The approval allows continued trading while Splash advances its transition into a cannabinoid wellness and pharmaceutical platform, supported by an equity line facility, a strategic investment in Avicanna, and exclusive worldwide licensing rights to CannEpil®.
Splash Beverage Group (NYSE American: SBEV) signed an exclusive global licensing deal with Argent BioPharma for CannEpil, a patent-protected cannabinoid therapy for drug-resistant epilepsy with existing access in Ireland, the UK, Germany and Australia.
The 20-year license includes worldwide commercialization rights, a $1 million strategic investment, preferred equity issuance and a 15% royalty on net revenue.
Splash Beverage Group (NYSE American: SBEV) signed an exclusive global licensing deal with Argent BioPharma for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil has established patient access in several European markets and an FDA Investigational New Drug number for future U.S. development.
The agreement grants Splash worldwide rights for at least 20 years, including sublicensing and next-generation products. Financing includes a $1 million strategic investment, ~$5 million debt forgiveness for Argent, $5.5 million in new Splash preferred equity, and a 15% net revenue royalty to Argent.
Splash Beverage Group (NYSE American: SBEV) completed a CDN$300,000 strategic investment in cannabinoid biopharmaceutical company Avicanna (TSX: AVCN), aligning with Splash’s transformation into a cannabinoid health, wellness, and healthcare platform.
The June 9, 2026 private placement gave Splash 2,000,000 common shares and 1,000,000 warrants. Avicanna offers the approved epilepsy treatment Trunerox, multiple clinical programs, the MyMedi.ca medical cannabis platform, vertically integrated Colombian manufacturing, and a debt-free balance sheet.
Splash Beverage Group (NYSE American: SBEV) provided an update on its NYSE American compliance process, strategic transaction efforts, and going concern disclosure.
The company has submitted a compliance plan after falling below stockholders’ equity standards, is actively pursuing cannabinoid wellness transactions, and disclosed an auditor going concern paragraph for 2025 financials.
Splash Beverage Group (NYSE American: SBEV) appointed Board member Brady Cobb as Interim CEO and principal executive officer, effective immediately, while President William Meissner will resign effective June 1, 2026.
The company is shifting toward a regulated wellness, cannabinoid, and functional consumer products platform while continuing to service its legacy beverage business.
According to Splash, the strategy targets hemp-derived CBD and, subject to regulatory and exchange approvals, medical cannabis, in a U.S. cannabis market estimated above $38 billion annually. Meissner will remain under a consulting agreement to support the transition.
Splash Beverage Group (NYSE American: SBEV) received an April 29, 2026 NYSE notice that it is not in compliance with the exchange's minimum shareholders' equity listing standard. The company must file a plan by May 29, 2026 to regain compliance and could obtain a cure period through January 29, 2027 if the plan is accepted.
The company has an outstanding letter of intent with Medterra CBD for a potential merger; a draft Merger Agreement has been delivered and is awaiting comments.
Oligomerix, a private company developing small molecule therapeutics for neurodegenerative and Alzheimer's diseases, has elected William Caple as its new Chairman of the Board of Directors. Caple brings over 30 years of executive leadership experience, notably in securing corporate investments and accelerating business plans.
Caple, currently a board member of Splash Beverage (NYSE:SBEV), founded Caple Advisory Solutions and has significant experience in corporate finance, business development, and M&A. His notable achievements include leading the IPO of OTG Software and orchestrating TaylorMade Golf's $1.8B acquisition by Centroid Investment Partners in 2021.
The appointment comes as Oligomerix advances its Phase 1 clinical human testing for treatments targeting tau in neurodegenerative disorders.
Splash Beverage Group (NYSE American:SBEV) has secured a significant retail expansion for its Pulpoloco Sangria through Total Wine & More, America's largest independent fine wine retailer. The authorization includes both Smooth Red and Crisp White Sangria varieties across 115+ stores in eight states: Arizona, California, Colorado, Florida, Illinois, Nevada, Texas, and Virginia.
The partnership with Total Wine & More represents a major distribution milestone for Pulpoloco Sangria, which combines authentic Spanish flavors with eco-friendly CartoCan packaging. This expansion aligns with the company's strategy to reach a broader audience of wine enthusiasts while maintaining its commitment to sustainability.